May 6, 2010 by Brian Orelli, PhDGood Deal Now, Bad Deal Later: It's a Biotech ThingAriad grabs cash now, but gives up long-term sales profits.
May 6, 2010 by Brian Orelli, PhDJohnson & Johnson, What Have You Done?We're not sure, but Congress wants to find out.
May 5, 2010 by Brian Orelli, PhDDoubled Revenue, but Not High GrowthAn acquisition and some rearrangements make Merck's revenue line sound better than it is.
May 5, 2010 by Brian Orelli, PhDDown 75%! The FDA Has the Final Say -- AlwaysInterMune's investors learn the hard way.
May 5, 2010 by Brian Orelli, PhDTeva's Double-Edged SwordNice quarter, but where will future growth come from?
May 4, 2010 by Brian Orelli, PhDEarnings Growth Trumps Revenue Growth, Except HereA solid quarter for Pfizer, but is there more in the tank?
May 3, 2010 by Brian Orelli, PhDWhile You Were Reveling in Dendreon's WinTwo other drugs received FDA decisions and another is expected shortly.
Apr 30, 2010 by Brian Orelli, PhDGrab the Right Biotech IPOsWhat investors should look for when peering through the murky IPO window.
Apr 30, 2010 by Brian Orelli, PhDBristol-Myers Still RocksHalf of its health-care reform bill damage just vanished.
Apr 30, 2010 by Brian Orelli, PhDNew CEO, Same Old Double-Digit IncreasesAnother strong quarter from Celgene.
Apr 30, 2010 by Brian Orelli, PhDInvest in Venture Capital. No Accreditation RequiredGet a piece of the action without betting the farm on start-ups.
Apr 30, 2010 by Brian Orelli, PhDPricey Provenge Pumps Up DendreonProstate cancer drug approved, but at what cost, and will insurance pay for it?
Apr 30, 2010 by Brian Orelli, PhDLiving the Blockbuster ModelAstraZeneca's top drugs provide top-line growth.
Apr 29, 2010 by Brian Orelli, PhDMegatrend? Check. Up by Double Digits? Check.Illumina illuminates another fine quarter.
Apr 29, 2010 by Brian Orelli, PhDEarnings Up 17%, but Here's Why You Should Be WorriedOne-time sales are no way to run a pharmaceutical business.
Apr 29, 2010 by Brian Orelli, PhDA Prescription to Investigate FurtherLet's not worry just yet about Medco's margins.
Apr 28, 2010 by Brian Orelli, PhDWhen Pleading Guilty Isn't Good EnoughLong-suffering Boston Scientific endures an epic legal fail.
Apr 28, 2010 by Brian Orelli, PhDWeekly Walk of Shame: A Wrinkle in Corporate BullyingBotox maker Allergan wants to recover $460,000 in court costs.
Apr 28, 2010 by Brian Orelli, PhDPfizer's $400 Million OverdoseNot getting a pediatric extension can be costly.
